Non-public fairness companies TPG and Blackstone BX just lately bid to amass Hologic Inc. HOLX, valuing the U.S. medical know-how firm at over $16 billion.
Hologic is an American medical know-how firm primarily targeted on girls’s well being. It sells medical units for diagnostics, surgical procedure, and imaging.
Whereas Hologic rejected the preliminary nonbinding supply, citing sources, the Monetary Occasions writes that the negotiations might resume.
Benzinga reached out to Hologic for feedback.
Additionally Learn: FDA Warns Hologic Over BioZorb Manufacturing Violations
The proposed buyout valued Hologic between $16.3 billion and $16.7 billion, together with debt, and would have priced shares at $70 to $72—nicely above the corporate’s closing worth of $54.28 on Friday.
The FT report provides that if profitable, the deal would have ranked among the many largest leveraged buyouts of the 12 months.
Regardless of the beneficiant premium, Hologic declined the strategy. Its inventory has dropped about 24% this 12 months, weighed down by U.S. tariffs and softening demand.
Hologic reported adjusted earnings of $1.03 per share for the second quarter of 2025, the identical as final 12 months, beating the consensus of $1.02. Gross sales decreased 1.2% 12 months over 12 months to $1.05 billion, beating the consensus of $1 billion.
Hologic lowered fiscal 2025 adjusted earnings per share steering from $4.25-4.35 to $4.15-4.25 in comparison with consensus of $4.26, primarily based on tariffs and geopolitical circumstances.
The corporate reaffirmed gross sales steering of $4.05 billion-$4.10 billion in comparison with the consensus of $4.08 billion.
Hologic expects third-quarter adjusted earnings of $1.04-1.07 per share versus consensus of $1.10 and gross sales of $1 billion-1.01 billion in comparison with the consensus of $1.03 billion.
The FT report famous that CEO MacMillan acknowledged within the firm’s current quarterly earnings name that the enterprise had endured “a tumultuous few months from a macroeconomic and coverage perspective.” Nonetheless, it emphasised that the agency is making progress.
Hologic has lengthy been considered as a attainable takeover goal. Activist investor Carl Icahn acquired a 12.5% stake in 2013, prompting the corporate to undertake a poison capsule technique. Icahn later secured two board seats and influenced management modifications, together with Steve MacMillan’s appointment as CEO.
Value Motion: HOLX inventory is up 15.1% at $62.48 on the final test Tuesday.
Learn Subsequent:
